HOMCOS:

		Contact Molecules for Homologous Proteins
[Summary Bars]	[Full Bars]	Site Table[80 %]	[Back to Search Page]	[Back to HOMCOS]
[Sites by Variants]	[SupCon3D]	[help]	seq_id(%): [0] [30] [40] [50] [60] [70] [80] [90] [95] [100]	[show] [download] [help]

PID

QueryLength

Homolgous Sequence in PDB

UniProt Query

TITLE

2993159

296

Q99836(MYD88_HUMAN)

RecName: Full=Myeloid differentiation primary response protein MyD88 ;

QUERYSEQ

MAAGGPGAGSAAPVSSTSSLPLAALNMRVRRRLSLFLNVRTQVAADWTALAEEMDFEYLEIRQLETQADPTGRLLDAWQGRPGASVGRLLELLTKLGRDDVLLELGPSIEEDCQKYILKQQQEEAEKPLQVAAVDSSVPRTAELAGITTL
DDPLGHMPERFDAFICYCPSDIQFVQEMIRQLEQTNYRLKLCVSDRDVLPGTCVWSIASELIEKRCRRMVVVVSDDYLQSKECDFQTKFALSLSPGAHQKRLIPIKYKAMKKEFPSILRFITVCDYTNPCTKSWFWTRLAKALSLP

[BLAST file for PDB] (plain) (bar) (multiple alignment) [BLAST for UniProt: (plain) (bar) (multiple alignment) (PSSM file) ]

  [n]:site number of query sequence.  [a]:amino acid of query sequence.  [s]:predicted secondary structure.
  [e]:predicted exposed/buried.  [acc]:predicted relative accesssibility(%).  [pdb]:PDB code of homologous structure.
  [contact_mols]:predicted binding molecules  [observed aa]:Observed amino acids among homologous sequences.  [feature table]:UniProt Feature Table
  [variant]:UniProt Human Variant.


M
AS
ATE
GV
GPVD
PVS
GRA
ACV
GE
S
ASGV
LPSA
PEDGLV
SDVPAT
SATIVP
DSFY
LMT
SNFH
SNAR
ILV
P
LVM
VARLT
A
L
N
VYMIC
GRNST
VF
R
RKH
RK
LV
SGC
L
FY
L
N
PV
RTDN
NAT
TAQVP
VTA
A
AS
DG
W
TMR
ASTRQVGL
LV
A
E
EANLK
ML
GDN
FYH
EDTS
YF
L
E
I
RKQ
NQRE
LFY
EQ
TKRDSA
RCYHALFQ
PADIQL
DCN
PSC
TF
RMGEVAS
KRSA
LVI
LY
EDTR
DAET
WG
QEK
GAKTPSR
RKL
PSCG
GRD
AS
TSQK
V
GA
RKGNQ
L
LV
ES
LIM
L
AKDTESR
KNLEQ
LVMA
EGDT
R
NKDEH
D
VI
LVI
ELTSMYKV
ED
L
GKRQ
PDEGVS
SLRIM
ILV
ED
EAD
D
CV
RQMK
KQR
YTH
LICMA
LEGRADFIKNPQSTVY
KRENADGILPQSTV
QKRADEGILNPSTV
QPENKL
KQNRADEGILPSTV
KEQRLADFGINPSTVY
READHNLFGIKPQSTVY
PASVLDEFGIKNQRTY
ENPAL
KSPLQ
P
LVIAEGKSTCDFHMNPQRY
QE
VSD
TPDAN
SAKERQV
VSI
DE
SA
SC
VQIFGADEKLNPRST
PHTADEGIKLNQRSV
RTKQWADEGILNPSV
TSILADEFGKNPQRVY
QKALSPNDEFGIRTVY
ED
LRQM
SAYQGMVE
GSR
IVL
T
TSLKI
PMLRESHY
DS
DLV
P
PLVEYQS
GLT
RHQGSL
GHTMAWILK
PSET
EKHNQD
TRLEVKDSMCH
YF
DH
AVI
FYC
VI
SCI
YHF
SCAL
EPASQKDRH
EQSKRNATH
DEN
ELSIRTFHQYA
ESDQYKTVALHN
FWAH
VALI
QENHRVLK
EDNFTL
MLIT
VLIMA
KPRQSD
QNYERPSGAMK
LVQ
EL
EQHGSNRM
TSGRFKENA
DNQEGVRTHPC
PFYARHTQ
GPKRSNTAL
LFYAGS
KRQTH
LC
CF
LVFI
HFQSADE
DEKLYQN
R
D
FVALSW
LIVATE
P
GER
GTKVAESIN
CAWIDGLSEFKNPQRTVY
VITLMAGSDEFKNPQRY
VWIFSTRQADEGKLNPY
DSEAT
INELVP
AITCSVD
SAQIVHLDG
DESNA
LSIAFGV
ISLTAGV
EQHNVRSAGL
KNSECTHRAGLV
RSHKNAGLDEFIPQTVY
CSALDEGIKPRTVFHMNQY
RKH
RKNADEGILPSTV
TLMVADEGIKNPRS
IVLA
VLFICM
VLI
LIV
ST
DPEQRSKN
NAHDGSE
FYS
LIVM
QKRDSNHTE
SDRGN
EPRKDTNYAS
WEAQD
CASV
KDRISLM
FYLH
EQS
LTMFYV
KLDREQ
FAQIEMLS
ASGL
LHQVSF
TSERDMQFAGL
LNEWSDKR
SAMQNECFGVL
PFDLHAS
GLAQSNYERD
AESRLQNDV
HRSNGIQL
ENRLQKDSHT
KIAGSVDR
RCGLNVA
LITV
IVEL
PLFVE
IVLR
KLVQEDSI
YLSKICR
KGEHQR
AKLSGIRPET
VIMLS
KPRLEDQS
KQADIREN
ERAPDSQL
FLYQ
PCKTIVYD
PSKRENA
LIEPAVKYD
LRKTQY
RKTDNS
FILPVMR
LMINY
TNYSL
YVTIRWKL
CKLVINPTR
DTKEN
YWGST
TLRKEVGYMPS
DNGHLRK
PESQADGL
CKLATVWGEYDFINPQRS
TQGSLHA
QKRDAGLS
EHSGKPAQVNL
WILGRAVM
F
W
TRKLVDAQE
RNKQ
LI
RAKQ
KAFNVTR
AS
LIM
SAL
LM
P

n	a	s	e	acc	pdb	contact_mols	observed aa	feature table	variant
1	M	-	-	-	-		M	DISORDER predicted by DISOPRED
2	A	-	-	-	-		AS	DISORDER predicted by DISOPRED
3	A	-	-	-	-		ATE	DISORDER predicted by DISOPRED
4	G	-	-	-	-		GV	DISORDER predicted by DISOPRED
5	G	-	-	-	-		GPVD	DISORDER predicted by DISOPRED
6	P	-	-	-	-		PVS	DISORDER predicted by DISOPRED
7	G	-	-	-	-		GRA	DISORDER predicted by DISOPRED
8	A	-	-	-	-		ACV	DISORDER predicted by DISOPRED
9	G	-	-	-	-		GE	DISORDER predicted by DISOPRED
10	S	-	-	-	-		S	DISORDER predicted by DISOPRED
11	A	-	-	-	-		ASGV	DISORDER predicted by DISOPRED
12	A	-	-	-	-		LPSA	DISORDER predicted by DISOPRED
13	P	-	-	-	-		PEDGLV	DISORDER predicted by DISOPRED
14	V	-	-	-	-		SDVPAT	DISORDER predicted by DISOPRED
15	S	-	-	-	-		SATIVP	DISORDER predicted by DISOPRED
16	S	-	-	-	-		DSFY	DISORDER predicted by DISOPRED
17	T	-	-	-	-		LMT
18	S	-	-	-	-		SNFH
19	S		e	97.7	6i3n_M		SNAR
20	L		b	16.9	6i3n_M		ILV
21	P		e	48.8	6i3n_M	homo	P
22	L	G	b	1.1	6i3n_M		LVM
23	A	G	e	50.0	6i3n_M	homo	VARLT
24	A	G	b	7.1	6i3n_M		A
25	L	S	b	3.4	6i3n_M	homo	L
26	N		e	41.2	6i3n_M	homo	N
27	M	H	e	58.0	6i3n_M	homo	VYMIC
28	R	H	e	52.6	6i3n_M	homo	GRNST
29	V	H	b	0.0	6i3n_M		VF
30	R	H	b	10.7	6i3n_M	homo	R
31	R	H	e	66.8	6i3n_M	hetero IRAK4_HUMAN homo	RKH
32	R	H	e	32.8	6i3n_M	homo	RK
33	L	H	b	2.8	6i3n_M		LV
34	S	H	b	5.5	6i3n_M	hetero IRAK4_HUMAN homo	SGC		S->Y:(0.0 %):US - dbSNP:rs1319438
35	L	H	e	56.2	6i3n_M	hetero IRAK4_HUMAN homo	L
36	F	H	b	17.2	6i3n_M	hetero IRAK4_HUMAN homo	FY
37	L	H	b	0.6	6i3n_M		L
38	N	T	e	31.5	6i3n_M	hetero IRAK4_HUMAN homo	N
39	V	S	e	62.0	6i3n_M	hetero IRAK4_HUMAN homo	PV		V->M:(0.0 %):US - dbSNP:rs7703876
40	R		e	53.4	6i3n_M	homo	RTDN
41	T		e	35.7	6i3n_M	hetero IRAK4_HUMAN homo	NAT
42	Q	S	e	94.4	6i3n_M	hetero IRAK4_HUMAN homo	TAQVP
43	V	S	e	92.0	6i3n_M	hetero IRAK4_HUMAN homo	VTA
44	A	S	e	55.4	6i3n_M	hetero IRAK4_HUMAN homo	A
45	A		b	19.6	6i3n_M		AS
46	D		b	3.1	6i3n_M	hetero IRAK4_HUMAN homo	DG
47	W	H	b	1.6	6i3n_M		W
48	T	H	b	19.5	6i3n_M	homo	TMR
49	A	H	b	19.6	6i3n_M	homo	ASTRQVGL
50	L	H	b	2.2	6i3n_M		LV
51	A	H	b	0.0	6i3n_M		A
52	E	H	e	65.3	6i3n_M	hetero IRAK4_HUMAN homo	E
53	E	H	e	34.2	6i3n_M		EANLK
54	M	T	b	1.9	6i3n_M		ML	DOMAIN /note="Death" DOMAIN /note="Death"
55	D	T	e	79.6	6i3n_M	homo	GDN	DOMAIN /note="Death" DOMAIN /note="Death"
56	F		b	12.0	6i3n_M	homo	FYH	DOMAIN /note="Death" DOMAIN /note="Death"
57	E		e	57.3	6i3n_M	homo	EDTS	DOMAIN /note="Death" DOMAIN /note="Death"
58	Y	H	e	65.2	6i3n_M	hetero IRAK4_HUMAN homo	YF	DOMAIN /note="Death" DOMAIN /note="Death"
59	L	H	e	61.2	6i3n_M	homo	L	DOMAIN /note="Death" DOMAIN /note="Death"
60	E	H	e	45.7	6i3n_M	homo	E	DOMAIN /note="Death" DOMAIN /note="Death"
61	I	H	b	8.8	6i3n_M	hetero IRAK4_HUMAN homo	I	DOMAIN /note="Death" DOMAIN /note="Death"
62	R	H	e	50.6	6i3n_M	hetero IRAK4_HUMAN homo	RKQ	DOMAIN /note="Death" DOMAIN /note="Death"
63	Q	H	e	51.0	6i3n_M	homo	NQRE	DOMAIN /note="Death" DOMAIN /note="Death"
64	L	H	b	5.1	6i3n_M	homo	LFY	DOMAIN /note="Death" DOMAIN /note="Death"
65	E	T	e	22.1	6i3n_M	hetero IRAK4_HUMAN homo	EQ	DOMAIN /note="Death" DOMAIN /note="Death"
66	T	T	e	71.4	6i3n_M		TKRDSA	DOMAIN /note="Death" DOMAIN /note="Death"
67	Q	S	e	36.7	6i3n_M	homo	RCYHALFQ	DOMAIN /note="Death" DOMAIN /note="Death"
68	A	S	e	79.5	6i3n_M		PADIQL	DOMAIN /note="Death" DOMAIN /note="Death"
69	D		e	34.0	6i3n_M	hetero IRAK4_HUMAN homo	DCN	DOMAIN /note="Death" DOMAIN /note="Death"
70	P	H	b	12.4	6i3n_M		PSC	DOMAIN /note="Death" DOMAIN /note="Death"
71	T	H	b	1.3	6i3n_M		TF	DOMAIN /note="Death" DOMAIN /note="Death"
72	G	H	b	0.0	6i3n_M		RMGEVAS	DOMAIN /note="Death" DOMAIN /note="Death"
73	R	H	e	34.0	6i3n_M	homo	KRSA	DOMAIN /note="Death" DOMAIN /note="Death"
74	L	H	b	0.0	6i3n_M		LVI	DOMAIN /note="Death" DOMAIN /note="Death"
75	L	H	b	1.1	6i3n_M		LY	DOMAIN /note="Death" DOMAIN /note="Death"
76	D	H	e	41.4	6i3n_M	homo	EDTR	DOMAIN /note="Death" DOMAIN /note="Death"
77	A	H	e	40.2	6i3n_M	homo	DAET	DOMAIN /note="Death" DOMAIN /note="Death"
78	W	T	b	3.2	6i3n_M		WG	DOMAIN /note="Death" DOMAIN /note="Death"
79	Q	S	e	35.7	6i3n_M	homo	QEK	DOMAIN /note="Death" DOMAIN /note="Death"
80	G	S	e	85.7	6i3n_M	homo	GAKTPSR	DOMAIN /note="Death" DOMAIN /note="Death"
81	R	S	e	33.6	6i3n_M	homo	RKL	DOMAIN /note="Death" DOMAIN /note="Death"
82	P	T	e	105.4	6i3n_M	homo	PSCG	DOMAIN /note="Death" DOMAIN /note="Death"
83	G	T	e	46.4	6i3n_M		GRD	DOMAIN /note="Death" DOMAIN /note="Death"
84	A		e	20.5	6i3n_M		AS	DOMAIN /note="Death" DOMAIN /note="Death"
85	S		b	13.3	6i3n_M		TSQK	DOMAIN /note="Death" DOMAIN /note="Death"
86	V	H	b	6.0	6i3n_M		V	DOMAIN /note="Death" DOMAIN /note="Death"
87	G	H	e	39.3	6i3n_M		GA	DOMAIN /note="Death" DOMAIN /note="Death"
88	R	H	e	28.5	6i3n_M		RKGNQ	DOMAIN /note="Death" DOMAIN /note="Death"
89	L	H	b	1.7	6i3n_M		L	DOMAIN /note="Death" DOMAIN /note="Death"
90	L	H	e	29.8	6i3n_M		LV	DOMAIN /note="Death" DOMAIN /note="Death"
91	E	H	e	57.8	6i3n_M		ES	DOMAIN /note="Death" DOMAIN /note="Death"
92	L	H	b	0.6	6i3n_M		LIM	DOMAIN /note="Death" DOMAIN /note="Death"
93	L	H	b	1.7	6i3n_M		L	DOMAIN /note="Death" DOMAIN /note="Death"	L->P:(0.0 %):LP/P Immunodeficiency 68 (IMD68) dbSNP:rs1378530 [MIM:612260]
94	T	H	e	46.8	6i3n_M		AKDTESR	DOMAIN /note="Death" DOMAIN /note="Death"
95	K	H	e	63.2	6i3n_M		KNLEQ	DOMAIN /note="Death" DOMAIN /note="Death"
96	L	T	e	20.8	6i3n_M		LVMA	DOMAIN /note="Death" DOMAIN /note="Death"
97	G	T	e	57.1	6i3n_M	hetero IRAK4_HUMAN homo	EGDT	DOMAIN /note="Death" DOMAIN /note="Death"
98	R		b	17.0	6i3n_M	hetero IRAK4_HUMAN homo	R	DOMAIN /note="Death" DOMAIN /note="Death"	R->C:(0.0 %):US - dbSNP:rs199396
99	D		e	59.3	6i3n_M	hetero IRAK4_HUMAN	NKDEH	DOMAIN /note="Death" DOMAIN /note="Death"
100	D	H	e	53.1	6i3n_M	hetero IRAK4_HUMAN homo	D	DOMAIN /note="Death" DOMAIN /note="Death"
101	V	H	b	1.3	6i3n_M		VI	DOMAIN /note="Death" DOMAIN /note="Death"
102	L	H	e	29.8	6i3n_M		LVI	DOMAIN /note="Death" DOMAIN /note="Death"
103	L	H	e	84.3	6i3n_M	hetero IRAK4_HUMAN	ELTSMYKV	DOMAIN /note="Death" DOMAIN /note="Death"
104	E	H	e	42.7	6i3n_M	hetero IRAK4_HUMAN homo	ED	DOMAIN /note="Death" DOMAIN /note="Death"
105	L	S	b	1.1	6i3n_M		L	DOMAIN /note="Death" DOMAIN /note="Death"
106	G	H	e	31.0	6i3n_M		GKRQ	DOMAIN /note="Death" DOMAIN /note="Death"
107	P	H	e	66.7	6i3n_M		PDEGVS	DOMAIN /note="Death" DOMAIN /note="Death"
108	S	H	b	18.8	6i3n_M		SLRIM	DOMAIN /note="Death" DOMAIN /note="Death"
109	I	H	b	4.7	6i3n_M		ILV	DOMAIN /note="Death" DOMAIN /note="Death"
110	E	H	e	67.8	6i3n_M		ED	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
111	E	H	e	49.7	6i3n_M		EAD	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
112	D	H	b	4.3	6i3n_M	homo	D	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
113	C	H	b	16.7	6i3n_M		CV	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
114	Q	H	e	55.6	6i3n_M		RQMK	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
115	K	H	e	50.9	6i3n_M	homo	KQR	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
116	Y	H	e	27.4	6i3n_M	homo	YTH	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
117	I	H	e	38.6	6i3n_M		LICMA	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
118	L	H	e	69.1	6i3n_M		LEGRADFIKNPQSTVY	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
119	K	H	e	85.8	6i3n_M	homo	KRENADGILPQSTV	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
120	Q	H	e	66.8	6i3n_M	homo	QKRADEGILNPSTV	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
121	Q		e	59.7	6i3n_M		QPENKL	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
122	Q	-	-	-	-		KQNRADEGILPSTV	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
123	E	-	-	-	-		KEQRLADFGINPSTVY	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
124	E	-	-	-	-		READHNLFGIKPQSTVY	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
125	A	-	-	-	-		PASVLDEFGIKNQRTY	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
126	E	-	-	-	-		ENPAL	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
127	K	-	-	-	-		KSPLQ	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
128	P	-	-	-	-		P	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
129	L	-	-	-	-		LVIAEGKSTCDFHMNPQRY	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
130	Q	-	-	-	-		QE	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
131	V	-	-	-	-		VSD	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
132	A	-	-	-	-		TPDAN	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
133	A	-	-	-	-		SAKERQV	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
134	V	-	-	-	-		VSI	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
135	D	-	-	-	-		DE	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
136	S	-	-	-	-		SA	REGION /note="Intermediate domain" REGION /note="Intermediate domain"	S->G:(0.0 %):US -;S->I:(0.0 %):US -
137	S	-	-	-	-		SC	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
138	V	-	-	-	-		VQIFGADEKLNPRST	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
139	P	-	-	-	-		PHTADEGIKLNQRSV	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
140	R	-	-	-	-		RTKQWADEGILNPSV	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
141	T	-	-	-	-		TSILADEFGKNPQRVY	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
142	A	-	-	-	-		QKALSPNDEFGIRTVY	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
143	E	-	-	-	-		ED	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
144	L	-	-	-	-		LRQM	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
145	A	-	-	-	-		SAYQGMVE	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
146	G	T	e	29.8	2js7_A		GSR	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
147	I	T	e	97.1	2js7_A		IVL	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
148	T		e	69.5	2js7_A		T	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
149	T	T	e	93.5	2js7_A		TSLKI	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
150	L	T	e	111.8	2js7_A		PMLRESHY	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
151	D		e	30.2	2js7_A		DS	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
152	D		e	30.2	2js7_A		DLV	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
153	P	T	e	69.0	2js7_A		P	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
154	L	T	e	30.9	2js7_A		PLVEYQS	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
155	G	S	e	67.9	2js7_A		GLT	REGION /note="Intermediate domain" REGION /note="Intermediate domain"
156	H		e	67.5	2js7_A		RHQGSL
157	M		b	12.6	2js7_A		GHTMAWILK
158	P	T	e	90.7	2js7_A		PSET
159	E	T	e	43.2	2js7_A		EKHNQD	DOMAIN /note="TIR" DOMAIN /note="TIR"
160	R		e	70.4	2js7_A		TRLEVKDSMCH	DOMAIN /note="TIR" DOMAIN /note="TIR"
161	F	E	b	3.3	2js7_A		YF	DOMAIN /note="TIR" DOMAIN /note="TIR"
162	D	E	b	0.0	2js7_A		DH	DOMAIN /note="TIR" DOMAIN /note="TIR"
163	A	E	b	0.0	2js7_A		AVI	DOMAIN /note="TIR" DOMAIN /note="TIR"
164	F	E	b	0.5	2js7_A		FYC	DOMAIN /note="TIR" DOMAIN /note="TIR"
165	I	E	b	0.0	2js7_A		VI	DOMAIN /note="TIR" DOMAIN /note="TIR"
166	C	E	b	0.0	2js7_A		SCI	DOMAIN /note="TIR" DOMAIN /note="TIR"
167	Y		b	0.4	2js7_A		YHF	DOMAIN /note="TIR" DOMAIN /note="TIR"
168	C		b	0.0	2js7_A		SCAL	DOMAIN /note="TIR" DOMAIN /note="TIR"
169	P	G	e	56.6	2js7_A		EPASQKDRH	DOMAIN /note="TIR" DOMAIN /note="TIR"
170	S	G	e	64.1	2js7_A		EQSKRNATH	DOMAIN /note="TIR" DOMAIN /note="TIR"
171	D	G	b	7.4	2js7_A		DEN	DOMAIN /note="TIR" DOMAIN /note="TIR"
172	I	H	e	22.2	2js7_A		ELSIRTFHQYA	DOMAIN /note="TIR" DOMAIN /note="TIR"
173	Q	H	e	65.3	2js7_A		ESDQYKTVALHN	DOMAIN /note="TIR" DOMAIN /note="TIR"
174	F	H	e	37.8	2js7_A		FWAH	DOMAIN /note="TIR" DOMAIN /note="TIR"
175	V	H	b	0.0	2js7_A		VALI	DOMAIN /note="TIR" DOMAIN /note="TIR"
176	Q	H	b	19.9	2js7_A		QENHRVLK	DOMAIN /note="TIR" DOMAIN /note="TIR"
177	E	H	e	23.1	2js7_A		EDNFTL	DOMAIN /note="TIR" DOMAIN /note="TIR"
178	M	H	b	0.0	2js7_A		MLIT	DOMAIN /note="TIR" DOMAIN /note="TIR"	M->I:(19.0 %):US - dbSNP:rs4128511
179	I	H	b	6.4	2js7_A		VLIMA	MUTAGEN /note="I->N: In Pococurante (Poc); abolished MYD88- dependent sensing of most Toll-like receptor (TLR) ligands." DOMAIN /note="TIR" MUTAGEN /note="I->N: In Pococurante (Poc); abolished MYD88- dependent sensing of most Toll-like receptor (TLR) ligands." DOMAIN /note="TIR"
180	R	H	e	57.7	2js7_A		KPRQSD	DOMAIN /note="TIR" DOMAIN /note="TIR"
181	Q	H	e	29.6	2js7_A		QNYERPSGAMK	DOMAIN /note="TIR" DOMAIN /note="TIR"
182	L	H	b	0.6	2js7_A		LVQ	DOMAIN /note="TIR" DOMAIN /note="TIR"
183	E	H	e	32.7	2js7_A		EL	DOMAIN /note="TIR" DOMAIN /note="TIR"
184	Q	T	e	64.8	2js7_A		EQHGSNRM	DOMAIN /note="TIR" DOMAIN /note="TIR"
185	T	S	e	44.2	2js7_A		TSGRFKENA	DOMAIN /note="TIR" DOMAIN /note="TIR"
186	N	S	b	18.2	2js7_A		DNQEGVRTHPC	DOMAIN /note="TIR" DOMAIN /note="TIR"
187	Y	S	e	51.3	2js7_A		PFYARHTQ	DOMAIN /note="TIR" DOMAIN /note="TIR"
188	R		e	89.3	2js7_A		GPKRSNTAL	DOMAIN /note="TIR" DOMAIN /note="TIR"
189	L		b	6.2	2js7_A		LFYAGS	DOMAIN /note="TIR" DOMAIN /note="TIR"
190	K		b	18.9	2js7_A		KRQTH	DOMAIN /note="TIR" DOMAIN /note="TIR"
191	L		b	3.4	2js7_A		LC	DOMAIN /note="TIR" DOMAIN /note="TIR"
192	C	E	b	0.0	2js7_A		CF	DOMAIN /note="TIR" DOMAIN /note="TIR"
193	V	E	b	0.0	2js7_A		LVFI	DOMAIN /note="TIR" DOMAIN /note="TIR"
194	S	S	e	23.4	2js7_A		HFQSADE	DOMAIN /note="TIR" DOMAIN /note="TIR"
195	D		e	23.5	2js7_A		DEKLYQN	DOMAIN /note="TIR" DOMAIN /note="TIR"
196	R		e	36.0	2js7_A		R	MUTAGEN /note="R->A: Reduced interaction with TIRAP, and strongly reduced activity. Strongly reduced interaction with TIRAP; when associated with A-288." DOMAIN /note="TIR" MUTAGEN /note="R->A: Reduced interaction with TIRAP, and strongly reduced activity. Strongly reduced interaction with TIRAP; when associated with A-288." DOMAIN /note="TIR"	R->C:(0.0 %):LP/P Immunodeficiency 68 (IMD68) dbSNP:rs1378530 [MIM:612260]
197	D	S	e	89.5	2js7_A		D	MUTAGEN /note="D->A: Slightly reduced activity." DOMAIN /note="TIR" MUTAGEN /note="D->A: Slightly reduced activity." DOMAIN /note="TIR"
198	V	S	e	56.0	2js7_A		FVALSW	DOMAIN /note="TIR" DOMAIN /note="TIR"
199	L	S	b	10.7	2js7_A		LIVATE	DOMAIN /note="TIR" DOMAIN /note="TIR"
200	P	S	e	39.5	2js7_A		P	DOMAIN /note="TIR" DOMAIN /note="TIR"
201	G	S	e	89.3	2js7_A		GER	DOMAIN /note="TIR" DOMAIN /note="TIR"
202	T		b	12.3	2js7_A		GTKVAESIN	DOMAIN /note="TIR" DOMAIN /note="TIR"
203	C	S	e	47.3	2js7_A		CAWIDGLSEFKNPQRTVY	MUTAGEN /note="C->S: Abolished interaction with E.coli TcpC without affecting ability to promote Toll-like receptor (TLR)- mediated cytokine production; when associated with S-280." DOMAIN /note="TIR" MUTAGEN /note="C->S: Abolished interaction with E.coli TcpC without affecting ability to promote Toll-like receptor (TLR)- mediated cytokine production; when associated with S-280." DOMAIN /note="TIR"
204	V		b	16.0	2js7_A		VITLMAGSDEFKNPQRY	DOMAIN /note="TIR" DOMAIN /note="TIR"	V->F:(1.0 %):US - dbSNP:rs7769954
205	W		b	17.5	2js7_A		VWIFSTRQADEGKLNPY	DOMAIN /note="TIR" DOMAIN /note="TIR"	W->R:(5.0 %):US -
206	S		b	7.0	2js7_A		DSEAT	DOMAIN /note="TIR" DOMAIN /note="TIR"	S->C:(0.0 %):US -
207	I		b	7.6	2js7_A		INELVP	DOMAIN /note="TIR" DOMAIN /note="TIR"	I->T:(0.0 %):US -
208	A		b	4.5	2js7_A		AITCSVD	DOMAIN /note="TIR" DOMAIN /note="TIR"
209	S	G	e	58.6	2js7_A		SAQIVHLDG	DOMAIN /note="TIR" DOMAIN /note="TIR"	S->R:(0.0 %):US -
210	E	G	e	75.4	2js7_A		DESNA	DOMAIN /note="TIR" DOMAIN /note="TIR"
211	L	G	e	44.9	2js7_A		LSIAFGV	DOMAIN /note="TIR" DOMAIN /note="TIR"
212	I	H	b	2.3	2js7_A		ISLTAGV	DOMAIN /note="TIR" DOMAIN /note="TIR"
213	E	H	e	25.6	2js7_A		EQHNVRSAGL	DOMAIN /note="TIR" DOMAIN /note="TIR"
214	K	H	e	49.1	2js7_A		KNSECTHRAGLV	DOMAIN /note="TIR" DOMAIN /note="TIR"
215	R	H	e	35.6	2js7_A		RSHKNAGLDEFIPQTVY	DOMAIN /note="TIR" DOMAIN /note="TIR"
216	C	E	b	0.7	2js7_A		CSALDEGIKPRTVFHMNQY	DOMAIN /note="TIR" DOMAIN /note="TIR"
217	R	E	e	41.1	2js7_A		RKH	MUTAGEN /note="R->A: Strongly reduced activity." DOMAIN /note="TIR" MUTAGEN /note="R->A: Strongly reduced activity." DOMAIN /note="TIR"
218	R	E	b	0.0	2js7_A		RKNADEGILPSTV	DOMAIN /note="TIR" DOMAIN /note="TIR"
219	M	E	b	0.0	2js7_A		TLMVADEGIKNPRS	DOMAIN /note="TIR" DOMAIN /note="TIR"	M->T:(33.0 %):US -
220	V	E	b	0.0	2js7_A		IVLA	DOMAIN /note="TIR" DOMAIN /note="TIR"
221	V	E	b	0.0	2js7_A		VLFICM	DOMAIN /note="TIR" DOMAIN /note="TIR"
222	V	E	b	0.0	2js7_A		VLI	DOMAIN /note="TIR" DOMAIN /note="TIR"
223	V		b	0.0	2js7_A		LIV	DOMAIN /note="TIR" DOMAIN /note="TIR"
224	S		b	0.0	2js7_A		ST	DOMAIN /note="TIR" DOMAIN /note="TIR"
225	D	H	e	29.0	2js7_A		DPEQRSKN	DOMAIN /note="TIR" DOMAIN /note="TIR"
226	D	H	b	16.0	2js7_A		NAHDGSE	DOMAIN /note="TIR" DOMAIN /note="TIR"
227	Y	H	b	0.0	2js7_A		FYS	DOMAIN /note="TIR" DOMAIN /note="TIR"
228	L	H	b	17.4	2js7_A		LIVM	DOMAIN /note="TIR" DOMAIN /note="TIR"
229	Q	H	e	65.8	2js7_A		QKRDSNHTE	DOMAIN /note="TIR" DOMAIN /note="TIR"
230	S	S	b	18.0	2js7_A		SDRGN	DOMAIN /note="TIR" DOMAIN /note="TIR"	S->N:(4.0 %):US - dbSNP:rs1353791
231	K	H	e	77.4	2js7_A		EPRKDTNYAS	DOMAIN /note="TIR" DOMAIN /note="TIR"
232	E	H	b	15.1	2js7_A		WEAQD	DOMAIN /note="TIR" DOMAIN /note="TIR"
233	C	H	b	5.3	2js7_A		CASV	DOMAIN /note="TIR" DOMAIN /note="TIR"
234	D	H	e	54.3	2js7_A		KDRISLM	DOMAIN /note="TIR" DOMAIN /note="TIR"
235	F	H	b	15.8	2js7_A		FYLH	DOMAIN /note="TIR" DOMAIN /note="TIR"
236	Q	H	b	0.0	2js7_A		EQS	DOMAIN /note="TIR" DOMAIN /note="TIR"
237	T	H	b	18.2	2js7_A		LTMFYV	DOMAIN /note="TIR" DOMAIN /note="TIR"
238	K	H	e	64.2	2js7_A		KLDREQ	DOMAIN /note="TIR" DOMAIN /note="TIR"
239	F	H	b	5.3	2js7_A		FAQIEMLS	DOMAIN /note="TIR" DOMAIN /note="TIR"
240	A	H	b	0.0	2js7_A		ASGL	DOMAIN /note="TIR" DOMAIN /note="TIR"
241	L	H	e	75.8	2js7_A		LHQVSF	DOMAIN /note="TIR" DOMAIN /note="TIR"
242	S	H	e	67.2	2js7_A		TSERDMQFAGL	DOMAIN /note="TIR" DOMAIN /note="TIR"
243	L	H	b	19.7	2js7_A		LNEWSDKR	DOMAIN /note="TIR" DOMAIN /note="TIR"
244	S		e	41.4	2js7_A		SAMQNECFGVL	MOD_RES /note="Phosphoserine" DOMAIN /note="TIR" MOD_RES /note="Phosphoserine" DOMAIN /note="TIR"
245	P	T	e	92.2	2js7_A		PFDLHAS	DOMAIN /note="TIR" DOMAIN /note="TIR"
246	G	T	e	54.8	2js7_A		GLAQSNYERD	DOMAIN /note="TIR" DOMAIN /note="TIR"
247	A	H	e	47.3	2js7_A		AESRLQNDV	DOMAIN /note="TIR" DOMAIN /note="TIR"
248	H	H	b	4.2	2js7_A		HRSNGIQL	DOMAIN /note="TIR" DOMAIN /note="TIR"
249	Q	H	b	18.4	2js7_A		ENRLQKDSHT	DOMAIN /note="TIR" DOMAIN /note="TIR"
250	K	H	e	41.5	2js7_A		KIAGSVDR	DOMAIN /note="TIR" DOMAIN /note="TIR"
251	R	T	b	11.9	2js7_A		RCGLNVA	DOMAIN /note="TIR" DOMAIN /note="TIR"
252	L	E	b	0.0	2js7_A		LITV	DOMAIN /note="TIR" DOMAIN /note="TIR"	L->P:(0.0 %):US Macroglobulinemia, Waldenstrom, 1 (WM1) dbSNP:rs3879072 [MIM:153600]
253	I	E	b	11.1	2js7_A		IVEL	DOMAIN /note="TIR" DOMAIN /note="TIR"
254	P	E	b	0.0	2js7_A		PLFVE	DOMAIN /note="TIR" DOMAIN /note="TIR"
255	I	E	b	0.0	2js7_A		IVLR	DOMAIN /note="TIR" DOMAIN /note="TIR"
256	K	E	b	11.8	2js7_A		KLVQEDSI	DOMAIN /note="TIR" DOMAIN /note="TIR"
257	Y	S	b	3.9	2js7_A		YLSKICR	DOMAIN /note="TIR" DOMAIN /note="TIR"
258	K	S	e	25.0	2js7_A		KGEHQR	DOMAIN /note="TIR" DOMAIN /note="TIR"
259	A		e	68.8	2js7_A		AKLSGIRPET	DOMAIN /note="TIR" DOMAIN /note="TIR"
260	M		e	21.7	2js7_A		VIMLS	DOMAIN /note="TIR" DOMAIN /note="TIR"
261	K		e	97.2	2js7_A		KPRLEDQS	DOMAIN /note="TIR" DOMAIN /note="TIR"
262	K		e	45.8	2js7_A		KQADIREN	DOMAIN /note="TIR" DOMAIN /note="TIR"
263	E		e	91.5	2js7_A		ERAPDSQL	DOMAIN /note="TIR" DOMAIN /note="TIR"
264	F		e	42.6	2js7_A		FLYQ	DOMAIN /note="TIR" DOMAIN /note="TIR"
265	P		e	25.6	2js7_A		PCKTIVYD	DOMAIN /note="TIR" DOMAIN /note="TIR"
266	S	T	e	69.5	2js7_A		PSKRENA	DOMAIN /note="TIR" DOMAIN /note="TIR"
267	I	T	b	12.3	2js7_A		LIEPAVKYD	DOMAIN /note="TIR" DOMAIN /note="TIR"
268	L	T	b	0.0	2js7_A		LRKTQY	DOMAIN /note="TIR" DOMAIN /note="TIR"
269	R	S	e	76.7	2js7_A		RKTDNS	DOMAIN /note="TIR" DOMAIN /note="TIR"
270	F		e	21.1	2js7_A		FILPVMR	DOMAIN /note="TIR" DOMAIN /note="TIR"
271	I	S	e	39.2	2js7_A		LMINY	DOMAIN /note="TIR" DOMAIN /note="TIR"
272	T	S	e	48.1	2js7_A		TNYSL	DOMAIN /note="TIR" DOMAIN /note="TIR"
273	V		e	34.0	2js7_A		YVTIRWKL	DOMAIN /note="TIR" DOMAIN /note="TIR"
274	C	E	b	7.3	2js7_A		CKLVINPTR	DOMAIN /note="TIR" DOMAIN /note="TIR"
275	D	E	b	8.6	2js7_A		DTKEN	DOMAIN /note="TIR" DOMAIN /note="TIR"
276	Y	T	e	22.2	2js7_A		YWGST	DOMAIN /note="TIR" DOMAIN /note="TIR"
277	T	T	e	33.8	2js7_A		TLRKEVGYMPS	DOMAIN /note="TIR" DOMAIN /note="TIR"
278	N		e	52.1	2js7_A		DNGHLRK	DOMAIN /note="TIR" DOMAIN /note="TIR"
279	P	T	e	72.1	2js7_A	metal MG	PESQADGL	DOMAIN /note="TIR" DOMAIN /note="TIR"
280	C	T	e	85.3	2js7_A		CKLATVWGEYDFINPQRS	MUTAGEN /note="C->S: Abolished interaction with E.coli TcpC without affecting ability to promote Toll-like receptor (TLR)- mediated cytokine production; when associated with S-203." DOMAIN /note="TIR" MUTAGEN /note="C->S: Abolished interaction with E.coli TcpC without affecting ability to promote Toll-like receptor (TLR)- mediated cytokine production; when associated with S-203." DOMAIN /note="TIR"
281	T	T	b	12.3	2js7_A		TQGSLHA	DOMAIN /note="TIR" DOMAIN /note="TIR"	T->P:(0.0 %):US -
282	K		e	44.8	2js7_A	metal MG	QKRDAGLS	MUTAGEN /note="K->A: Slightly reduced activity." DOMAIN /note="TIR" MUTAGEN /note="K->A: Slightly reduced activity." DOMAIN /note="TIR"
283	S	S	e	84.4	2js7_A		EHSGKPAQVNL	DOMAIN /note="TIR" DOMAIN /note="TIR"
284	W	S	e	48.2	2js7_A		WILGRAVM	DOMAIN /note="TIR" DOMAIN /note="TIR"
285	F	H	b	1.4	2js7_A		F	DOMAIN /note="TIR" DOMAIN /note="TIR"
286	W	H	b	8.8	2js7_A		W	DOMAIN /note="TIR" DOMAIN /note="TIR"
287	T	H	e	20.1	2js7_A		TRKLVDAQE	DOMAIN /note="TIR" DOMAIN /note="TIR"
288	R	H	e	55.3	2js7_A		RNKQ	MUTAGEN /note="R->A: Slightly reduced activity, and reduced interaction with TIRAP. Strongly reduced interaction with TIRAP; when associated with A-196." DOMAIN /note="TIR" MUTAGEN /note="R->A: Slightly reduced activity, and reduced interaction with TIRAP. Strongly reduced interaction with TIRAP; when associated with A-196." DOMAIN /note="TIR"
289	L	H	b	1.7	2js7_A		LI	DOMAIN /note="TIR" DOMAIN /note="TIR"
290	A	H	b	0.0	2js7_A		RAKQ	DOMAIN /note="TIR" DOMAIN /note="TIR"
291	K	H	e	34.0	2js7_A		KAFNVTR	DOMAIN /note="TIR" DOMAIN /note="TIR"
292	A	H	e	23.2	2js7_A		AS	DOMAIN /note="TIR" DOMAIN /note="TIR"
293	L	H	b	0.0	2js7_A		LIM	DOMAIN /note="TIR" DOMAIN /note="TIR"
294	S	H	e	20.3	2js7_A		SAL
295	L	S	e	37.6	2js7_A		LM
296	P		e	29.5	2js7_A		P

Contact Molecules for Homologous Proteins

Site Table[80 %]